Michele Ghidini, MD, PhD, Policlinico di Milano, Milan, Italy, comments on the potential role of ctDNA in the management of colorectal cancer. Whilst ctDNA has only been investigated in pre-clinical settings, it may benefit patients with targetable mutations and predict response in clinical practice. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.